[논문]Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study

Clayton, Anita H; Baker, Ross A; Sheehan, John J; Cain, Zachary J; Forbes, Robert A; Marler, Sabrina Vogel; Marcus, Ronald; Berman, Robert M; Thase, Michael E

doi:10.1186/1756-0500-7-459

Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study 원문보기

BMC research notes, v.7, 2014년, pp.459 - 459

Clayton, Anita H (Department of Psychiatry and Neurobehavioral Sciences, The University of Virginia, Charlottesville, 2955 Ivy Rd, Northridge Suite 210, Charlottesville VA 22903, USA) , Baker, Ross A (Otsuka Pharmaceutical Development & Commercialization, 1 University Square Drive, Princeton NJ 08540, USA) , Sheehan, John J (Bristol-Myers Squibb, Plainsboro, 777 Scudders Mill Road, Plainsboro NJ 08536, USA) , Cain, Zachary J (Bristol-Myers Squibb, Plainsboro, 777 Scudders Mill Road, Plainsboro NJ 08536, USA) , Forbes, Robert A (Otsuka Pharmaceutical Development & Commercialization, 1 University Square Drive, Princeton NJ 08540, USA) , Marler, Sabrina Vogel (Bristol-Myers Squibb, Wallingford, CT, USA) , Marcus, Ronald (Bristol-Myers Squibb, Wallingford, CT, USA) , Berman, Robert M (Bristol-Myers Squibb, Wallingford, CT, USA) , Thase, Michael E (Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market Street, Suite 670, Philadelphia, PA 19104, USA)

Abstract ▼ AI-Helper

BackgroundThis post hoc analysis assessed the safety, tolerability and effectiveness of long-term treatment with aripiprazole adjunctive to either bupropion or selective serotonin reuptake inhibitors (SSRIs)/serotonin–norepinephrine reuptake inhibitors (SNRIs) in patients with major depressive disorder (MDD).MethodsData from de novo patients (did not participate in 2 previous studies) in a 52-week, open-label safety study of adjunctive aripiprazole after documented inadequate response to 1–4 antidepressant treatments (ADTs; SSRI, SNRI, or bupropion) were analyzed post hoc. Assessments included safety and tolerability, sexual functioning (Massachusetts General Hospital Sexual Functioning Inventory [MGH-SFI]) and Clinical Global Impressions–Severity (CGI-S).ResultsForty-seven patients received bupropion plus aripiprazole and 245 received an SSRI/SNRI plus aripiprazole; 19 (40.4%) and 78 (31.8%), respectively, completed 52 weeks of treatment, and 46 and 242, respectively, received ≥1 dose of study medication (safety sample). Median time to discontinuation (any reason) was 184.0 days. Overall, 97.8% of patients in the bupropion group and 93.8% in the SSRI/SNRI group experienced ≥1 adverse event. The most common treatment-emergent adverse events were fatigue (26.1%) and somnolence (21.7%) with bupropion and fatigue (23.6%) and akathisia (23.6%) with an SSRI/SNRI. Mean change in body weight at week 52 (observed cases) was +3.1 kg for bupropion and +2.4 kg for an SSRI/SNRI. Treatment-emergent, potentially clinically relevant abnormalities in fasting glucose occurred in 8.3% of patients with bupropion and 17.4% with an SSRI/SNRI; for abnormalities in fasting total cholesterol, the incidence was 25.0% and 34.7%, respectively. Mean (SE) change from baseline in fasting glucose was 1.4 (1.9) mg/dL with bupropion and 2.7 (1.5) mg/dL with an SSRI/SNRI. Baseline MGH-SFI item scores indicated less severe impairment with bupropion versus an SSRI/SNRI; in both groups most MGH-SFI items exhibited improvement at week 52. Mean CGI-S improvement at week 52 (last observation carried forward) was -1.4 with bupropion and -1.5 with an SSRI/SNRI (efficacy sample).ConclusionsThere were no unexpected AEs with long-term adjunctive aripiprazole therapy when added to either bupropion or SSRIs/SNRIs, and symptom improvement was similar between ADT groups. Sexual functioning in patients with MDD on antidepressants was also modestly improved after adding aripiprazole.Trial registrationClinicalTrials.gov: NCT00095745 (November 9, 2004).

주제어

참고문헌 (26)

Burris KD Molski TF Xu C Ryan E Tottori K Kikuchi T Yocca FD Molinoff PB Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J Pharmacol Exp Ther 2002 302 381 389 12065741

상세보기
Shapiro DA Renock S Arrington E Chiodo LA Liu LX Sibley DR Roth BL Mailman R Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacol 2003 28 1400 1411

상세보기
Jordan S Koprivica V Dunn R Tottori K Kikuchi T Altar CA In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function Eur J Pharmacol 2004 483 45 53 14709325

상세보기
Jordan S Koprivica V Chen R Tottori K Kikuchi T Altar CA The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor Eur J Pharmacol 2002 441 137 140 12063084

상세보기
Tadori Y Forbes RA McQuade RD Kikuchi T Characterization of aripiprazole partial agonist activity at human dopamine D(3) receptors Eur J Pharmacol 2008 597 27 33 18831971

상세보기
Berman RM Marcus RN Swanink R McQuade RD Carson WH Corey-Lisle PK Khan A The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study J Clin Psychiatry 2007 68 843 853 17592907

상세보기
Marcus RN McQuade RD Carson WH Hennicken D Fava M Simon JS Trivedi MH Thase ME Berman RM The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study J Clin Psychopharmacol 2008 28 156 165 18344725

상세보기
Berman R Fava M Thase M Swanink R McQuade R Carson W Adson D Taylor L Hazel J Marcus R Aripiprazole augmentation in major depression: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants CNS Spectrums 2009 14 197 206 19407731
Berman RM Thase ME Trivedi MH Hazel JA Marler SV McQuade RD Carson W Baker RA Marcus RN Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder Neuropsychiatr Dis Treat 2011 7 303 312 21655344

상세보기
Fava M Rush AJ Thase ME Clayton A Stahl SM Pradko JF Johnston JA 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL Prim Care Companion J Clin Psychiatry 2005 7 106 113 16027765

상세보기
American Psychiatric Association Practice Guideline for the Treatment of Patients with Major Depressive Disorder 2010 American Psychiatric Publishing: Third edition
Clayton AH Montejo AL Major depressive disorder, antidepressants, and sexual dysfunction J Clin Psychiatry 2006 67 Suppl 6 33 37 16848675
Clayton AH Recognition and assessment of sexual dysfunction associated with depression J Clin Psychiatry 2001 62 Suppl 3 5 9 11229452
Dhillon S Yang LP Curran MP Spotlight on bupropion in major depressive disorder CNS Drugs 2008 22 613 617 18547129

상세보기
Thase ME Haight BR Richard N Rockett CB Mitton M Modell JG VanMeter S Harriett AE Wang Y Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials J Clin Psychiatry 2005 66 974 981 16086611

상세보기
Clayton AH Pradko JF Croft HA Montano CB Leadbetter RA Bolden-Watson C Bass KI Donahue RM Jamerson BD Metz A Prevalence of sexual dysfunction among newer antidepressants J Clin Psychiatry 2002 63 357 366 12000211

상세보기
Papakostas GI The efficacy, tolerability, and safety of contemporary antidepressants J Clin Psychiatry 2010 71 Suppl E1 e03 20371030
Schlaepfer TE Agren H Monteleone P Gasto C Pitchot W Rouillon F Nutt DJ Kasper S The hidden third: improving outcome in treatment-resistant depression J Psychopharmacol 2012 26 587 602 22236505

상세보기
Uher R Perlis RH Henigsberg N Zobel A Rietschel M Mors O Hauser J Dernovsek MZ Souery D Bajs M Maier W Aitchison KJ Farmer A McGuffin P Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms Psychol Med 2012 42 967 980 21929846

상세보기
Adjunctive antipsychotics for major depression Med Lett Drugs Ther 2011 53 74 75 21921872

상세보기
Fava M Rush AJ Trivedi MH Nierenberg AA Thase ME Sackeim HA Quitkin FM Wisniewski S Lavori PW Rosenbaum JF Kupfer DJ Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study Psychiatr Clin North Am 2003 26 457 494 x 12778843

상세보기
Guy W Clinical Global Impressions (CGI) ECDEU Assessment Manual for Psychopharmacology US Department of Health, Education, and Welfare Publication (ADM) 76–338 1976 Rockville, MD: National Institute of Mental Health 218 222
Labbate LA Lare SB Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire Psychother Psychosom 2001 70 221 225 11408842

상세보기
Sleight P Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them! Curr Control Trials Cardiovasc Med 2000 1 25 27 11714402

상세보기
Fava M Dording CM Baker RA Mankoski R Tran QV Forbes RA Eudicone JM Owen R Berman RM Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies Prim Care Companion CNS Disord 2011 13 1 PCC.10m00994 21731833
Sokolski KN Adjunctive aripiprazole for bupropion-resistant major depression Ann Pharmacother 2008 42 1124 1129 18492784

상세보기

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (26)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

연관된 기능

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트